Clinical Trials Browser

Completed × INDUSTRY × Doxorubicin × Clear all

Burkitt Lymphoma, Leukemia

Hodgkin Disease, Lymphoma

HER2-positive Early Breast Cancer

Lymphoma, T-Cell, Peripheral

Breast Neoplasms

Ovarian Neoplasms

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Lymphoma, B-Cell

Lymphoma, Non-Hodgkin

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis, Sarcoma

Neoplasm Metastasis, Sarcoma

Breast Neoplasms

Hodgkin Disease

Multiple Myeloma, Recurrence

Triple Negative Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Ovarian Neoplasms

Limb-girdle muscular dystrophy, type 2C, Lymphoma, Large B-Cell, Diffuse

Chemotherapy-induced Neutropenia

Triple Negative Breast Neoplasms

Lymphoma, Non-Hodgkin

Breast Neoplasms

Lymphoma, Non-Hodgkin

Breast Neoplasms, Sarcoma

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Lymphoma, Non-Hodgkin

Neoplasm Metastasis

Lymphoma, T-Cell, Peripheral

Neoplasms, Neuroendocrine Tumors

Clinical Trials

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

APHINITY

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma

ANNOUNCE

MK-3475-775

SELENE

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

IMpassion050

FeDeriCa

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

CheckMate 205

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

IMpassion031

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

JAVELIN Ovarian 200

ROBUST

NEUGR-003

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

ECHELON-2

ATLANTIS

ReLive

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

A Study of Olaratumab in Japanese Participants With Advanced Cancer

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

SCHEARLY

KEYNOTE 173

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors